• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Quantum-Si Reports Third Quarter 2024 Financial Results

    11/12/24 7:30:00 AM ET
    $QSI
    Industrial Machinery/Components
    Industrials
    Get the next $QSI alert in real time by email

    Sales Pipeline is Accelerating and New Kits Remain on Track for Q4 Launch

    Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the third quarter ended September 30, 2024.

    Press Release Highlights

    • Reported revenue of $787,000 for the third quarter of 2024
    • Announced that Liberate Bio has integrated Platinum® Next-Generation Sequencing into their platform for developing novel gene therapies with improved targeting capabilities
    • Announced appointments of industry veteran Todd Bennett as Chief Commercial Officer ("CCO"), John Vieceli, Ph.D. as Chief Product Officer and Lindsay Thompson as Chief Human Resources Officer
    • Highlighted Platinum-based advances in proteomic analysis presented at Human Proteome Organization World Congress 2024 in Dresden, Germany
    • Highlighted a manuscript from researchers at the University of Virginia published on BioRxiv highlighting Platinum's capability to discriminate peptide variants at single amino acid resolution
    • New library preparation kit and barcoding kit remain on track for launch before year end
    • Highlighted the Company's upcoming Investor Day on Wednesday, November 20, 2024, beginning at 10:00 a.m. ET

    "We are pleased to see continued adoption of Platinum across multiple market segments, including academic research, pharma/biotech and most recently, adoption by our first customer from the contract research organization market. Under the leadership of our new CCO, there has been clear improvement in commercial execution and the overall acceleration of our sales pipeline," said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. "Even with this acceleration, we, like others in the tools space, have observed some lengthening of the sales cycle in the third quarter, making it likely that we will not achieve our full year guided revenue range of $3.7 million to $4.2 million. We have clear strategies in place that we believe will allow us to get as close to the guidance range as possible and despite the potential short fall, we remain very confident in the long-term commercial opportunity for Platinum and the growth of the proteomics market in general. We are excited for the future and believe that we will continue to deliver solid quarter over quarter growth as we move forward."

    Hawkins continued, "In addition, we continue to execute on our innovation roadmap and are on track to deliver two new kits by end of the year, which we believe will continue to drive broader market adoption. We are looking forward to revealing more details on our exciting technology roadmap and expanding commercial opportunities at our upcoming Investor Day on November 20th."

    Third Quarter 2024 Financial Results

    For the third quarter of 2024, the Company recorded revenue of $787,000. Gross profit was $367,000 and gross margin was 47%. For the nine months ended September 30, 2024, the Company recorded revenue of $1.9 million, gross profit of $990,000, and gross margin of 53%. The periodic gross margin rate is expected to be variable in the near term as the Company works through the initial stages of commercialization as well as the timing and mix of product sales between instruments and consumable kits.

    Total operating expenses were $28.5 million in the third quarter of 2024, compared to $27.3 million for the same period in the prior year, and $78.9 million for the nine months ended September 30, 2024, compared to $83.6 million for the same period in the prior year. Adjusted total operating expenses were $26.0 million in the third quarter of 2024 compared to $23.9 million for the same period in the prior year, and adjusted total operating expenses for the nine months ended September 30, 2024 were $72.3 million compared to $72.6 million for the same period in the prior year. The Company has successfully reduced overall adjusted operating expenses on a year to date basis while funding the ramp up in commercialization efforts. This reduction was driven by the Company's 2023 R&D realignment initiative to streamline and focus R&D efforts on delivering product enhancements to customers. Overall, the Company has been able to reduce core areas of spend while accelerating R&D focus, efficiency, and delivery while still funding the Company's full commercial launch of its Platinum® instrument.

    Net loss was $25.3 million in the third quarter of 2024, compared to a net loss of $24.7 million in the same period of the prior year, and a net loss of $67.9 million for the nine months ended September 30, 2024, compared to a net loss of $73.9 million for the same period in the prior year. Adjusted EBITDA was negative $24.5 million in the third quarter of 2024, compared to negative $22.6 million in the same period of the prior year, and negative $67.7 million for the nine months ended September 30, 2024, compared to negative $69.2 million for the same period in the prior year. A reconciliation of the non-GAAP financial measures adjusted total operating expenses and adjusted EBITDA is provided in a table included in this press release.

    As of September 30, 2024, the Company's cash and cash equivalents and investments in marketable securities were $196.3 million.

    Financial Guidance

    The Company provided updated full year 2024 financial guidance for adjusted operating expenses and cash usage as follows:

    Adjusted total operating expenses

    Approximately $100 million

    Total cash usage

    Approximately $92 million

    The Company also updated its expectation that the balance in cash and cash equivalents and investments in marketable securities of $196.3 million as of September 30, 2024 will provide a runway into the second half of 2026.

    Webcast and Conference Call Information

    Quantum-Si will host a conference call to discuss its third quarter 2024 financial results on Tuesday, November 12, 2024, at 8:00 a.m. Eastern Time. Individuals interested in listening to the conference call may do so by joining the live webcast in the Investors section of the Quantum-Si website under Events & Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will be available for replay following the event.

    Investor Day

    The Company will host an Investor Day on Wednesday, November 20th beginning at 10:00 a.m. ET. To access the event, a live audio webcast will be available on the Investors section of the Company's website.

    About Quantum-Si Incorporated

    Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

    Use of Non-GAAP Financial Measures

    This press release presents the non-GAAP financial measures "adjusted total operating expenses" and "adjusted EBITDA." The most directly comparable measures for these non-GAAP financial measures are total operating expenses and net loss. The Company has included below adjusted total operating expenses, which presents the Company's total operating expenses after excluding goodwill impairment, stock-based compensation and restructuring costs. In addition, adjusted EBITDA further excludes interest, taxes, depreciation, amortization, dividend income, unrealized and realized gains and losses on marketable securities, changes in fair value of warrant liabilities and other income or expense.

    A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding the Company's financial condition and results of operations is included as Exhibit 99.2 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on November 12, 2024.

    Forward Looking Statements

    This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company's Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company's ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product development and commercialization activities; the commercialization and adoption of the Company's existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company's commercialized Platinum® protein sequencing instrument and kits and the Company's other products once commercialized; the Company's ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing lease, license, manufacture and supply agreements; the Company's ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company's estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

    QUANTUM-SI INCORPORATED

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands, except share and par value amounts)

    (unaudited)

     

     

    September 30,

    2024

     

    December 31,

    2023

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    42,268

     

     

    $

    133,860

     

    Marketable securities

     

    154,076

     

     

     

    123,876

     

    Accounts receivable, net of allowance of $0 and $0, respectively

     

    1,022

     

     

     

    368

     

    Inventory

     

    4,091

     

     

     

    3,945

     

    Prepaid expenses and other current assets

     

    4,371

     

     

     

    4,261

     

    Total current assets

     

    205,828

     

     

     

    266,310

     

    Property and equipment, net

     

    16,254

     

     

     

    16,275

     

    Internally developed software, net

     

    —

     

     

     

    532

     

    Operating lease right-of-use assets

     

    13,677

     

     

     

    14,438

     

    Other assets

     

    695

     

     

     

    695

     

    Total assets

    $

    236,454

     

     

    $

    298,250

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    2,153

     

     

    $

    1,766

     

    Accrued payroll and payroll-related costs

     

    4,603

     

     

     

    4,943

     

    Accrued contracted services

     

    2,133

     

     

     

    1,519

     

    Accrued expenses and other current liabilities

     

    2,839

     

     

     

    1,815

     

    Current portion of operating lease liabilities

     

    3,614

     

     

     

    1,566

     

    Total current liabilities

     

    15,342

     

     

     

    11,609

     

    Warrant liabilities

     

    357

     

     

     

    1,274

     

    Operating lease liabilities

     

    10,211

     

     

     

    13,737

     

    Other long-term liabilities

     

    24

     

     

     

    11

     

    Total liabilities

     

    25,934

     

     

     

    26,631

     

     

     

     

     

    Stockholders' equity

     

     

     

    Class A Common stock, $0.0001 par value; 600,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 122,775,352 and 121,832,417 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively

     

    12

     

     

     

    12

     

    Class B Common stock, $0.0001 par value; 27,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 19,937,500 shares issued and outstanding as of September 30, 2024 and December 31, 2023

     

    2

     

     

     

    2

     

    Additional paid-in capital

     

    773,873

     

     

     

    767,239

     

    Accumulated other comprehensive loss

     

    153

     

     

     

    -

     

    Accumulated deficit

     

    (563,520

    )

     

     

    (495,634

    )

    Total stockholders' equity

     

    210,520

     

     

     

    271,619

     

    Total liabilities and stockholders' equity

    $

    236,454

     

     

    $

    298,250

     

    QUANTUM-SI INCORPORATED

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (in thousands, except per share amounts)

    (unaudited)

     

     

    Three months ended

    September 30,

     

    Nine months ended

    September 30,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Revenue:

     

     

     

     

     

     

     

    Product

    $

    764

     

     

    $

    216

     

     

    $

    1,776

     

     

    $

    654

     

    Service

     

    23

     

     

     

    7

     

     

     

    90

     

     

     

    28

     

    Total revenue

     

    787

     

     

     

    223

     

     

     

    1,866

     

     

     

    682

     

     

     

     

     

     

     

     

     

    Cost of revenue

     

    420

     

     

     

    115

     

     

     

    876

     

     

     

    372

     

     

     

     

     

     

     

     

     

    Gross profit

     

    367

     

     

     

    108

     

     

     

    990

     

     

     

    310

     

    Operating expenses:

     

     

     

     

     

     

     

    Research and development

     

    16,171

     

     

     

    16,587

     

     

     

    42,653

     

     

     

    50,588

     

    Selling, general and administrative

     

    12,284

     

     

     

    10,696

     

     

     

    36,236

     

     

     

    33,010

     

    Total operating expenses

     

    28,455

     

     

     

    27,283

     

     

     

    78,889

     

     

     

    83,598

     

    Loss from operations

     

    (28,088

    )

     

     

    (27,175

    )

     

     

    (77,899

    )

     

     

    (83,288

    )

    Dividend and interest income

     

    2,688

     

     

     

    2,572

     

     

     

    9,149

     

     

     

    7,274

     

    Unrealized gain on trading securities

     

    —

     

     

     

    1,953

     

     

     

    —

     

     

     

    8,302

     

    Realized loss on trading securities

     

    —

     

     

     

    (1,901

    )

     

     

    —

     

     

     

    (6,489

    )

    Change in fair value of warrant liabilities

     

    121

     

     

     

    (162

    )

     

     

    917

     

     

     

    (81

    )

    Other income (expense), net

     

    9

     

     

     

    (15

    )

     

     

    (10

    )

     

     

    370

     

    Loss before provision for income taxes

     

    (25,270

    )

     

     

    (24,728

    )

     

     

    (67,843

    )

     

     

    (73,912

    )

    Provision for income taxes

     

    (43

    )

     

     

    —

     

     

     

    (43

    )

     

     

    —

     

    Net loss

    $

    (25,313

    )

     

    $

    (24,728

    )

     

    $

    (67,886

    )

     

    $

    (73,912

    )

     

     

     

     

     

     

     

     

    Net loss per common share attributable to common stockholders, basic and diluted

    $

    (0.18

    )

     

    $

    (0.17

    )

     

    $

    (0.48

    )

     

    $

    (0.52

    )

    Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted

     

    142,399

     

     

     

    141,660

     

     

     

    142,039

     

     

     

    141,154

     

     

     

     

     

     

     

     

     

    Other comprehensive gain (loss):

     

     

     

     

     

     

     

    Net unrealized gain on marketable securities, net of tax

    $

    163

     

     

    $

    —

     

     

    $

    163

     

     

    $

    —

     

    Foreign currency translation adjustment

     

    (3

    )

     

     

    —

     

     

     

    (10

    )

     

     

    —

     

    Total other comprehensive gain, net of tax

     

    160

     

     

     

    —

     

     

     

    153

     

     

     

    —

     

    Comprehensive loss

    $

    (25,153

    )

     

    $

    (24,728

    )

     

    $

    (67,733

    )

     

    $

    (73,912

    )

    QUANTUM-SI INCORPORATED

    RECONCILIATION OF U.S. GAAP TO NON-GAAP FINANCIAL MEASURES

    (in thousands)

    (unaudited)

     

     

    Three months ended

    September 30,

     

    Nine months ended

    September 30,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Net loss

    $

    (25,313

    )

     

    $

    (24,728

    )

     

    $

    (67,886

    )

     

    $

    (73,912

    )

    Adjustments to reconcile to EBITDA:

     

     

     

     

     

     

     

    Dividend and interest income

     

    (2,688

    )

     

     

    (2,572

    )

     

     

    (9,149

    )

     

     

    (7,274

    )

    Depreciation and amortization

     

    1,158

     

     

     

    1,170

     

     

     

    3,606

     

     

     

    3,063

     

    Income tax provision

     

    43

     

     

     

    —

     

     

     

    43

     

     

     

    —

     

    EBITDA

     

    (26,800

    )

     

     

    (26,130

    )

     

     

    (73,386

    )

     

     

    (78,123

    )

    Adjustments to reconcile to Adjusted EBITDA:

     

     

     

     

     

     

     

    Unrealized gain on trading securities

     

    —

     

     

     

    (1,953

    )

     

     

    —

     

     

     

    (8,302

    )

    Realized loss on trading securities

     

    —

     

     

     

    1,901

     

     

     

    —

     

     

     

    6,489

     

    Change in fair value of warrant liabilities

     

    (121

    )

     

     

    162

     

     

     

    (917

    )

     

     

    81

     

    Other (income) expense, net

     

    (9

    )

     

     

    15

     

     

     

    10

     

     

     

    (370

    )

    Stock-based compensation

     

    2,394

     

     

     

    1,141

     

     

     

    6,403

     

     

     

    6,914

     

    Restructuring costs

     

    23

     

     

     

    2,251

     

     

     

    197

     

     

     

    4,131

     

    Adjusted EBITDA

    $

    (24,513

    )

     

    $

    (22,613

    )

     

    $

    (67,693

    )

     

    $

    (69,180

    )

     

    Three months ended

    September 30,

     

    Nine months ended

    September 30,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Total operating expenses

    $

    28,455

     

     

    $

    27,283

     

     

    $

    78,889

     

     

    $

    83,598

     

    Adjustments to reconcile to Adjusted total operating expenses:

     

     

     

     

     

     

     

    Stock-based compensation

     

    (2,394

    )

     

     

    (1,141

    )

     

     

    (6,403

    )

     

     

    (6,914

    )

    Restructuring costs

     

    (23

    )

     

     

    (2,251

    )

     

     

    (197

    )

     

     

    (4,131

    )

    Adjusted total operating expenses

    $

    26,038

     

     

    $

    23,891

     

     

    $

    72,289

     

     

    $

    72,553

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241112920059/en/

    Get the next $QSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $QSI

    DatePrice TargetRatingAnalyst
    2/7/2025$3.75Buy
    Alliance Global Partners
    12/8/2023$3.00Buy
    H.C. Wainwright
    9/25/2023$3.50 → $2.00Buy → Hold
    Canaccord Genuity
    10/20/2021$13.00Buy
    Canaccord Genuity
    More analyst ratings

    $QSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Hawkins Jeffrey Alan sold $32,846 worth of shares (23,707 units at $1.39), decreasing direct ownership by 0.89% to 2,646,716 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      3/24/25 6:48:37 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • General Counsel & Corp. Secr. Lapointe Christian sold $6,783 worth of shares (4,896 units at $1.39), decreasing direct ownership by 0.50% to 983,480 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      3/24/25 6:42:56 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Chief Financial Officer Keyes Jeffry R. sold $11,951 worth of shares (8,626 units at $1.39), decreasing direct ownership by 0.72% to 1,188,194 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      3/24/25 6:34:27 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Keyes Jeffry R. bought $43,465 worth of shares (50,000 units at $0.87), increasing direct ownership by 13% to 446,820 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:25 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • President & CEO Hawkins Jeffrey Alan bought $21,272 worth of shares (25,000 units at $0.85), increasing direct ownership by 3% to 1,003,757 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:28 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Director Kummeth Charles R. bought $148,459 worth of shares (170,000 units at $0.87), increasing direct ownership by 92% to 355,000 units (SEC Form 4)

      4 - Quantum-Si Inc (0001816431) (Issuer)

      8/13/24 6:01:24 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    SEC Filings

    See more
    • Quantum-Si Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Quantum-Si Inc (0001816431) (Filer)

      4/10/25 4:49:41 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • SEC Form DEFA14A filed by Quantum-Si Incorporated

      DEFA14A - Quantum-Si Inc (0001816431) (Filer)

      3/20/25 4:12:20 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • SEC Form DEF 14A filed by Quantum-Si Incorporated

      DEF 14A - Quantum-Si Inc (0001816431) (Filer)

      3/20/25 4:07:34 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Financials

    Live finance-specific insights

    See more
    • Quantum-Si to Report First Quarter 2025 Financial Results on May 15, 2025

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the first quarter 2025 on Thursday, May 15, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personali

      4/24/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Reports Fourth Quarter and Full Year 2024 Financial Results

      Achieves First Quarterly Revenue Over $1 Million Completes Capital Raises of $86 Million Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced financial results for the fourth quarter and full year ended December 31, 2024. Press Release Highlights Reported revenue of $1.2 million for the fourth quarter of 2024 and $3.1 million for the full year 2024 (representing a 183% full year-over-year growth) Raised capital of over $86 million between the fourth quarter of 2024 and first week of 2025 (extending cash runway into the second half of 2027) Announced the launch of Platinum® Pro in January 2025, with shipp

      3/3/25 4:05:00 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 3, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in numbe

      2/12/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners initiated coverage on Quantum-Si with a new price target

      Alliance Global Partners initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.75

      2/7/25 8:29:38 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • H.C. Wainwright initiated coverage on Quantum-Si with a new price target

      H.C. Wainwright initiated coverage of Quantum-Si with a rating of Buy and set a new price target of $3.00

      12/8/23 7:55:31 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Quantum-Si from Buy to Hold and set a new price target of $2.00 from $3.50 previously

      9/25/23 9:04:14 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quantum-Si to Report First Quarter 2025 Financial Results on May 15, 2025

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced that it will report financial results for the first quarter 2025 on Thursday, May 15, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a conference call to discuss financial results and provide a business update on the same day at 4:30 PM ET. Individuals interested in listening to the conference call may do so by joining the live webcast on the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personali

      4/24/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Begins Shipping Platinum® Pro, Advancing Accessibility in Next-Gen Protein Sequencing™

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces the start of shipments for its latest benchtop sequencer, Platinum® Pro. This groundbreaking instrument offers protein analysis with single-molecule precision, aiming to make Next-Gen Protein Sequencing™ more accessible to laboratories worldwide. Platinum Pro delivers a comprehensive solution for sequencing and analyzing proteins through a simple, integrated workflow. Building upon the foundation of innovation established by the original Platinum, the new system introduces advanced features tailored to the evolving needs of researchers and biopharmaceutical customers. Key

      3/26/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si to Participate in DNAnexus Webinar on Large Scale Proteomics in Multi-Omics Research

      Validate multi-omics findings at the single-molecule level with Next-Gen Protein Sequencing™ Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, announces participation in an upcoming DNAnexus webinar focused on the role of proteomics in multi-omics research. This discussion will explore how the integration of proteomics data with other omics datasets is driving new discoveries in disease research, including cancer. When: March 25, 2025, at 8 a.m. PT/11 a.m. ET Attendees will learn about: The growing impact of proteomics in multi-omics analysis Applications for cancer and other disease research Technologies and strategies fo

      3/20/25 8:00:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Quantum-Si Incorporated

      SC 13D/A - Quantum-Si Inc (0001816431) (Subject)

      9/17/24 4:24:56 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Quantum-Si Incorporated

      SC 13G/A - Quantum-Si Inc (0001816431) (Subject)

      6/28/24 5:16:32 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G filed by Quantum-Si Incorporated

      SC 13G - Quantum-Si Inc (0001816431) (Subject)

      2/13/24 9:41:18 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials

    $QSI
    Leadership Updates

    Live Leadership Updates

    See more
    • Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to serve as independent Chairman of the Board of Directors

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced the appointment of Charles ("Chuck") Kummeth to the role of independent Chairman of the Board, effective May 27, 2024. Mr. Kummeth has over 35 years of leadership experience in Life Sciences most recently as President and CEO of Bio-Techne. During Mr. Kummeth's tenure at Bio-Techne, he oversaw tremendous growth across all aspects of the business including annual revenue growth from $300M to over $1.1B, growth in the employee base from 800 to over 3,000, and the successful execution of 19 acquisitions, all while maintaining a 35% or better EBITDA level. Under Mr. Ku

      5/30/24 4:05:00 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Appoints Former Illumina and Cisco Systems Executive, Paula Dowdy, to its Board of Directors

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing CompanyTM, today announced the appointment of Paula Dowdy, a senior executive with more than 35 years of experience across life sciences, enterprise software, and technology industries, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321183506/en/Paula Dowdy (Photo: Business Wire) Ms. Dowdy currently serves on the Board of Directors for SPT Labtech, a world leading lab automation tools company based in the UK and is an advisor at EQT Life Sciences, one of Europe's leading investors targeting innovative

      3/21/24 4:05:00 PM ET
      $QSI
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Introduces World's First Next-Generation Protein Sequencer™ in Japan with Addition of New Distributor

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company™, today announced that it has entered into an agreement with a new distributor who will make the company's protein sequencing instrument, Platinum® available for the first time in Japan. TOMY Digital Biology Co., Ltd., a renowned importer and distributor with a rich history dating back to the 1950s, will distribute Quantum-Si's next-generation protein sequencer™ and associated consumables throughout Japan. "Working with Quantum-Si marks a pivotal moment for TOMY Digital Biology, aligning with our commitment to advancing life sciences. We're poised to empower Japanese researchers wit

      1/18/24 8:30:00 AM ET
      $QSI
      Industrial Machinery/Components
      Industrials